The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

High blood pressure is one of the world’s leading causes of death, yet many people struggle to keep it under control. A new ...

The commission’s leadership includes Richard Carpiano, Ph.D., M.P.H., professor of public policy at the University of ...

Spencer, a new commission convened by the medical journal The Lancet will recommend how to build more resilient communities ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

While better knowledge and healthcare facilities have reduced delays in starting cancer treatment in India, the decline was ...

A Personal View published in The Lancet Oncology challenges the long-standing perception of metastatic brain cancer, calling ...

Lancet Commission chair Eliah Aronoff-Spencer (front) of UC San Diego attends the UN Science Summit in the fall of 2024 with Lancet Commission co-chairs Richard Carpiano (center back) of UC Riverside ...

Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

Advancements and Projections in the Global Blood Micro-Sampling Medical Devices Market: Insights, Trends, Opportunities, and ...

Statins help people manage high cholesterol levels, but many experts want to know if these drugs can also support brain ...